Literature DB >> 9792208

Cytotoxic etherphospholipid analogues.

D Berkovic1.   

Abstract

1. Alkyllyso-derivatives of physiologic cell membrane phospholipids show remarkable cytostatic and cytotoxic activity on many malignant tumor cell lines and tumors in vitro and in vivo. Three of these etherphospholipid analogues have already been tested in clinical phase II studies and one of these compounds, hexadecylphosphocholine (HePC), is now commercially available as a drug for the treatment of mammary carcinoma in Germany. 2. Etherphospholipid analogues possess a variety of interesting biological characteristics like induction of cellular maturation, inhibition of tumor cell invasion or modulation of the immune response with high potential value for tumor therapy. 3. Though there have been extensive investigations on the biochemical mode of action of these substances, the precise mechanism responsible for the majority of biological effects has not yet been identified. 4. In recent years growing evidence has been accumulated that etherphospholipid analogues substantially interfere with intracellular signal transduction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792208     DOI: 10.1016/s0306-3623(98)00081-0

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  11 in total

Review 1.  Structural insights into phospholipase C-β function.

Authors:  Angeline M Lyon; John J G Tesmer
Journal:  Mol Pharmacol       Date:  2013-07-23       Impact factor: 4.436

2.  Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.

Authors:  Stefan R Vink; Jan H M Schellens; Wim J van Blitterswijk; Marcel Verheij
Journal:  Invest New Drugs       Date:  2005-08       Impact factor: 3.850

3.  Inhibition of Plasmodium falciparum choline kinase by hexadecyltrimethylammonium bromide: a possible antimalarial mechanism.

Authors:  Vinay Choubey; Pallab Maity; Mithu Guha; Sanjay Kumar; Kumkum Srivastava; Sunil Kumar Puri; Uday Bandyopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

Review 4.  Novel inhibitors of AKT: assessment of a different approach targeting the pleckstrin homology domain.

Authors:  E J Meuillet
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

5.  2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor.

Authors:  L Hanus; S Abu-Lafi; E Fride; A Breuer; Z Vogel; D E Shalev; I Kustanovich; R Mechoulam
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  Inositoylated platelet-activating factor (Ino-C2-PAF) modulates dynamic lymphocyte-endothelial cell interactions and alleviates psoriasis-like skin inflammation in two complementary mouse models.

Authors:  Susann Forkel; Margarete Schön; Annette Hildmann; Anna Claßen; Swen-Malte John; Kerstin Danker; Michael P Schön
Journal:  J Invest Dermatol       Date:  2014-04-08       Impact factor: 8.551

Review 7.  Enzyme-triggered nanomedicine: drug release strategies in cancer therapy.

Authors:  Thomas L Andresen; David H Thompson; Thomas Kaasgaard
Journal:  Mol Membr Biol       Date:  2010-10-13       Impact factor: 2.857

8.  Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.

Authors:  José M Jiménez-López; Pablo Ríos-Marco; Carmen Marco; Josefa L Segovia; María P Carrasco
Journal:  Lipids Health Dis       Date:  2010-03-25       Impact factor: 3.876

9.  Testing the hypothesis that amphiphilic antineoplastic lipid analogues act through reduction of membrane curvature elastic stress.

Authors:  Marcus Dymond; George Attard; Anthony D Postle
Journal:  J R Soc Interface       Date:  2008-11-06       Impact factor: 4.118

10.  Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells.

Authors:  Andrean L Simons; Arlene D Parsons; Katherine A Foster; Kevin P Orcutt; Melissa A Fath; Douglas R Spitz
Journal:  J Oncol       Date:  2009-09-02       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.